Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00819637
Other study ID # ASRC947
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 2009
Est. completion date November 2009

Study information

Verified date April 2023
Source Henry Ford Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the best dose of nebulized arformoterol, a quick onset but long acting beta agonist, for use in treating acute bronchospasm in asthmatics presenting to the the Emergency Department. Also this study will evaluate the side effect and safety profile of arformoterol when used in this situation.


Description:

Acute bronchospasm associated with exacerbations of asthma is a common problem. Currently the mainstay of treatment is inhalation albuterol, either levalbuterol or racemic mixture, in repetitive fashion depending on the resolution of the airways obstruction. Formoterol is a long-acting (>12 hours) selective beta2-agonist that has a very rapid onset of bronchodilatation (<3 minutes and thus similar to that produced by albuterol). Patients with acute bronchospasm could benefit from the prn use of formoterol as they would receive acute relief of their symptoms and this would last for a prolonged time period. Additionally formoterol has been reported to be 28-109 times as potent as albuterol and safe at doses of 54ug in healthy subjects and asthmatics. Racemic formoterol structurally has 2 chiral centers and thus is composed of 4 enantiomers. The RR form (or arformoterol) is the active bronchodilator and it is not clear what the physiologic actions of the other 3 enantiomers are. This study is the first to evaluate nebulized arformoterol solution for therapy of acute asthmatics presenting to the Emergency Department.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date November 2009
Est. primary completion date November 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Signed informed consent - FEV1 between 20 and 60% predicted after having received 5 mg of albuterol and 0.5 mg of atrovent as nebulized standard of care therapy - Male or female between the ages of 18 and 45 - Asthma diagnosed by a physician and present for at least 6 months - oxygen saturation greater or equal to 90% on room air - Non smoker or < 10 pack-year history - No other cause for wheezing/sob as determined by the treating physician Exclusion Criteria: - Clinical evidence or history of hepatic, renal, cardiovascular, GI, endocrine, metabolic or CNS disease which might interfere with the conduct of the study - Acute respiratory failure or other significant pathology of the pulmonary system - Female subjects who are pregnant or lactating - Currently receiving therapy for a psychiatric disorder - Subjects with a known sensitivity to formoterol (racemic or RR) or albuterol (racemic or lev) - History of hospitalization for asthma within 2 months or treatment for acute asthma in an ED within 2 weeks of study entry - Past or current use of disallowed medications - Participation in an investigational study within 30 days

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
arformoterol (RR formoterol)
Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses. Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
placebo
Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
levalbuterol
Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.

Locations

Country Name City State
United States Henry Ford Hospital Emergency Department Detroit Michigan

Sponsors (2)

Lead Sponsor Collaborator
Henry Ford Health System Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Averaged Mean Percent Change From Baseline FEV1 and PEFR (Percent Predicted and Absolute) After the 3 Doses of Study Drug 1 hour
Secondary Most Effective Dose of Inhalation Arformoterol for Treating Acute Bronchospasm in Asthmatics by Evaluating the Averaged Mean Percent Change From Baseline % Predicted FEV1 After 3 Doses of Study Medication in Each of the 3 Groups The study was terminated early and therefore secondary outcome measures were not obtained. 1 hour
Secondary Number of Participants Treated With Arformoteral in Acute Asthma Exacerbation as a Measure of Safety and Tolerability. The study was terminated early and therefore secondary outcome measures were not obtained. 5 hours
Secondary The Mean Percent Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug 1 hour
Secondary The Mean Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug The study was terminated early and therefore secondary outcome measures were not obtained. 1 hour
Secondary The Peak Change (Liters) and Peak Percent Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug 1 hour
Secondary The Time to Onset of a 15% Improvement in FEV1 for Each Dose (Individual and Cumulative) and Total Dose of Study Medication to Reach This 5 hour
Secondary The Time Required to Achieve a FEV1 and PEFR > 60% Predicted for Each Dose (Individual and Cumulative) 5 hours
Secondary Percent of Responders (Defined as Those Discharged Following Treatment Who Did Not Require Additional Therapy in the ED) The 2 subjects enrolled were both discharged home after study protocol completion, with no further treatment required in the ED setting. 5 hours
Secondary Percent of Patients in Each Group Requiring Additional Therapies After the First Hour of Study Drug Treatments 2 subjects were enrolled. Neither required additional asthma treatment after the 1st hour of study drug teatments. 5 hours
Secondary All of the Primary and Secondary Endpoints Partitioned by the Presenting PFT in Quartiles and the Presenting S Albuterol Levels in Quartiles 5 hours
Secondary Pharmacokinetics of Arformoterol in This Clinical Setting 5 hours
See also
  Status Clinical Trial Phase
Completed NCT01429415 - Magnesium Nebulization Utilization in Management of Pediatric Asthma Phase 2
Completed NCT01196377 - Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study N/A
Completed NCT00733473 - Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing Phase 4
Completed NCT00733317 - Budesonide for Emergency Treatment of Acute Wheezing in Children Phase 4
Completed NCT01695031 - Feasibility of an ED Initiated Online Asthma Management Program for Urban Teens N/A
Recruiting NCT04016220 - Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma Phase 1
Active, not recruiting NCT06005337 - Supporting Parents to Choose Wisely N/A
Completed NCT01079000 - Emergency Department (ED)-Directed Interventions to Improve Asthma Outcomes N/A
Completed NCT00922350 - Heliox and Posture in Patients With Asthma N/A
Completed NCT03698630 - Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children Phase 4
Completed NCT01868113 - Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial Phase 3
Completed NCT01016444 - Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms
Completed NCT00393367 - Budesonide Inhalation Suspension for Acute Asthma in Children Phase 4
Completed NCT03369119 - Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children Phase 4
Completed NCT01304901 - Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children. Phase 4
Completed NCT01403467 - Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation Phase 4